Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Crombez Eric | EVP and Chief Medical Officer | May 02 '24 | Sale | 43.66 | 354 | 15,456 | 48,431 | May 03 03:23 PM | Crombez Eric | EVP and Chief Medical Officer | Apr 18 '24 | Sale | 44.10 | 142 | 6,262 | 48,785 | Apr 19 04:35 PM | Kassberg Thomas Richard | CBO & EVP | Mar 11 '24 | Sale | 49.93 | 11,509 | 574,644 | 252,823 | Mar 12 01:41 PM | Fust Matthew K | Director | Mar 07 '24 | Sale | 50.88 | 12,195 | 620,443 | 14,860 | Mar 11 12:54 PM | Harris Erik | EVP & Chief Commercial Officer | Mar 01 '24 | Sale | 53.76 | 4,768 | 256,328 | 67,163 | Mar 05 08:08 PM | Pinion John Richard | See Remarks | Mar 01 '24 | Sale | 53.76 | 4,173 | 224,340 | 89,268 | Mar 05 08:15 PM | Parschauer Karah Herdman | EVP and Chief Legal Officer | Mar 01 '24 | Sale | 53.76 | 3,756 | 201,923 | 67,340 | Mar 05 08:22 PM | Crombez Eric | EVP and Chief Medical Officer | Mar 01 '24 | Sale | 53.76 | 1,238 | 66,555 | 48,927 | Mar 05 08:10 PM | Kassberg Thomas Richard | CBO & EVP | Mar 01 '24 | Sale | 53.76 | 1,011 | 54,351 | 264,332 | Mar 05 08:19 PM | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Mar 01 '24 | Sale | 53.76 | 341 | 18,332 | 41,380 | Mar 05 08:13 PM | KAKKIS EMIL D | President & CEO | Feb 07 '24 | Sale | 45.00 | 30,000 | 1,350,000 | 539,770 | Feb 08 03:49 PM | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Jan 02 '24 | Option Exercise | 21.00 | 3,000 | 63,000 | 27,892 | Jan 02 04:06 PM | KAKKIS EMIL D | President & CEO | Dec 29 '23 | Sale | 47.87 | 30,000 | 1,436,100 | 569,770 | Jan 02 04:07 PM | Kassberg Thomas Richard | CBO & EVP | Oct 23 '23 | Option Exercise | 6.86 | 39,878 | 273,563 | 286,738 | Oct 24 05:22 PM | Kassberg Thomas Richard | CBO & EVP | Oct 23 '23 | Sale | 32.78 | 39,878 | 1,307,201 | 246,860 | Oct 24 05:22 PM | KAKKIS EMIL D | President & CEO | Oct 19 '23 | Option Exercise | 6.86 | 47,853 | 328,272 | 647,029 | Oct 23 05:14 PM | KAKKIS EMIL D | President & CEO | Oct 19 '23 | Sale | 33.52 | 47,853 | 1,604,033 | 599,743 | Oct 23 05:14 PM | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sep 07 '23 | Option Exercise | 21.00 | 2,000 | 42,000 | 25,777 | Sep 11 01:52 PM | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sep 07 '23 | Sale | 40.80 | 2,163 | 88,249 | 23,614 | Sep 11 01:52 PM | Harris Erik | EVP & Chief Commercial Officer | Sep 05 '23 | Sale | 37.96 | 6,000 | 227,760 | 51,281 | Sep 06 05:51 PM | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sep 01 '23 | Sale | 37.15 | 970 | 36,032 | 23,777 | Sep 06 05:50 PM | Sanders Corazon (Corsee) D. | Director | Jun 30 '23 | Sale | 46.76 | 585 | 27,355 | 8,985 | Jun 30 02:34 PM | Harris Erik | EVP & Chief Commercial Officer | Jun 19 '23 | Sale | 48.20 | 305 | 14,701 | 57,281 | Jun 21 06:17 PM | Sanders Corazon (Corsee) D. | Director | Jun 08 '23 | Sale | 51.65 | 1,485 | 76,700 | 9,570 | Jun 09 02:31 PM |
|